Literature DB >> 25682594

Impaired cytotoxicity associated with defective natural killer cell differentiation in myelodysplastic syndromes.

Maryam Hejazi1, Angela R Manser1, Julia Fröbel2, Andrea Kündgen2, Xiaoyi Zhao1, Kathrin Schönberg1, Ulrich Germing2, Rainer Haas2, Norbert Gattermann2, Markus Uhrberg3.   

Abstract

Natural killer cells are well known to mediate anti-leukemic responses in myeloid leukemia but their role in myelodysplastic syndromes is not well understood. Here, in a cohort of newly diagnosed patients (n=75), widespread structural and functional natural killer cell defects were identified. One subgroup of patients (13%) had a selective deficiency of peripheral natural killer cells (count <10/mm(3) blood) with normal frequencies of T and natural killer-like T cells. Natural killer cell-deficient patients were predominantly found in high-risk subgroups and deficiency of these cells was significantly associated with poor prognosis. In the second subgroup, comprising the majority of patients (76%), natural killer cells were present but exhibited poor cytotoxicity. The defect was strongly associated with reduced levels of perforin and granzyme B. Notably, natural killer cell function and arming of cytotoxic granules could be fully reconstituted by in vitro stimulation. Further phenotypic analysis of these patients revealed an immature natural killer cell compartment that was biased towards CD56(bright) cells. The residual CD56(dim) cells exhibited a significant increase of the unlicensed NKG2A(-)KIR(-) subset and a striking reduction in complexity of the repertoire of killer cell immunoglobulin-like receptors. Taken together, these results suggest that the widespread defects in natural killer cell function occurring in patients with myelodysplastic syndromes are mostly due to either unsuccessful or inefficient generation of mature, functionally competent natural killer cells, which might contribute to disease progression through impaired immune surveillance. Copyright© Ferrata Storti Foundation.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25682594      PMCID: PMC4420213          DOI: 10.3324/haematol.2014.118679

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  34 in total

1.  The CD107 mobilization assay: viable isolation and immunotherapeutic potential of tumor-cytolytic NK cells.

Authors:  M Uhrberg
Journal:  Leukemia       Date:  2005-05       Impact factor: 11.528

2.  Natural killer cell activity in preleukaemia.

Authors:  F Porzsolt; H Heimpel
Journal:  Lancet       Date:  1982-02-20       Impact factor: 79.321

3.  Human natural killer cells with polyclonal lectin and immunoglobulinlike receptors develop from single hematopoietic stem cells with preferential expression of NKG2A and KIR2DL2/L3/S2.

Authors:  J S Miller; V McCullar
Journal:  Blood       Date:  2001-08-01       Impact factor: 22.113

4.  International scoring system for evaluating prognosis in myelodysplastic syndromes.

Authors:  P Greenberg; C Cox; M M LeBeau; P Fenaux; P Morel; G Sanz; M Sanz; T Vallespi; T Hamblin; D Oscier; K Ohyashiki; K Toyama; C Aul; G Mufti; J Bennett
Journal:  Blood       Date:  1997-03-15       Impact factor: 22.113

5.  Comparative studies of human FcRIII-positive and negative natural killer cells.

Authors:  A Nagler; L L Lanier; S Cwirla; J H Phillips
Journal:  J Immunol       Date:  1989-11-15       Impact factor: 5.422

6.  Human NK cell education by inhibitory receptors for MHC class I.

Authors:  Nicolas Anfossi; Pascale André; Sophie Guia; Christine S Falk; Sophie Roetynck; C Andrew Stewart; Violette Breso; Coralie Frassati; Denis Reviron; Derek Middleton; François Romagné; Sophie Ugolini; Eric Vivier
Journal:  Immunity       Date:  2006-08-10       Impact factor: 31.745

7.  Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application.

Authors:  Toshiaki Hayashi; Teru Hideshima; Masaharu Akiyama; Klaus Podar; Hiroshi Yasui; Noopur Raje; Shaji Kumar; Dharminder Chauhan; Steven P Treon; Paul Richardson; Kenneth C Anderson
Journal:  Br J Haematol       Date:  2005-01       Impact factor: 6.998

8.  Cytolytic function and survival of natural killer cells are severely altered in myelodysplastic syndromes.

Authors:  J-J Kiladjian; E Bourgeois; I Lobe; T Braun; G Visentin; J-H Bourhis; P Fenaux; S Chouaib; A Caignard
Journal:  Leukemia       Date:  2006-03       Impact factor: 11.528

9.  Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants.

Authors:  Loredana Ruggeri; Marusca Capanni; Elena Urbani; Katia Perruccio; Warren D Shlomchik; Antonella Tosti; Sabrina Posati; Daniela Rogaia; Francesco Frassoni; Franco Aversa; Massimo F Martelli; Andrea Velardi
Journal:  Science       Date:  2002-03-15       Impact factor: 47.728

10.  Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy.

Authors:  K Kärre; H G Ljunggren; G Piontek; R Kiessling
Journal:  Nature       Date:  1986 Feb 20-26       Impact factor: 49.962

View more
  19 in total

1.  NK cell development in a human stem cell niche: KIR expression occurs independently of the presence of HLA class I ligands.

Authors:  Xiaoyi Zhao; Sandra Weinhold; Jens Brands; Maryam Hejazi; Özer Degistirici; Gesine Kögler; Roland Meisel; Markus Uhrberg
Journal:  Blood Adv       Date:  2018-10-09

2.  Selective and Potent CDK8/19 Inhibitors Enhance NK-Cell Activity and Promote Tumor Surveillance.

Authors:  Marco H Hofmann; Rajeswaran Mani; Harald Engelhardt; Maria A Impagnatiello; Sebastian Carotta; Marc Kerenyi; Seila Lorenzo-Herrero; Jark Böttcher; Dirk Scharn; Heribert Arnhof; Andreas Zoephel; Renate Schnitzer; Thomas Gerstberger; Michael P Sanderson; Girish Rajgolikar; Swagata Goswami; Sumithira Vasu; Peter Ettmayer; Segundo Gonzalez; Mark Pearson; Darryl B McConnell; Norbert Kraut; Natarajan Muthusamy; Jürgen Moll
Journal:  Mol Cancer Ther       Date:  2020-02-05       Impact factor: 6.261

3.  A 4-lncRNA scoring system for prognostication of adult myelodysplastic syndromes.

Authors:  Chi-Yuan Yao; Ching-Hsuan Chen; Huai-Hsuan Huang; Hsin-An Hou; Chien-Chin Lin; Mei-Hsuan Tseng; Chein-Jun Kao; Tzu-Pin Lu; Wen-Chien Chou; Hwei-Fang Tien
Journal:  Blood Adv       Date:  2017-08-16

4.  The prognostic value of the controlling nutritional status score in patients with myelodysplastic syndrome.

Authors:  Jin Qian; Jing Wang; Feng Cheng; Hong-Feng Guo; Jun Xia; Xin Zhou
Journal:  Support Care Cancer       Date:  2022-08-08       Impact factor: 3.359

Review 5.  Microenvironmental Features Driving Immune Evasion in Myelodysplastic Syndromes and Acute Myeloid Leukemia.

Authors:  Georgios Petros Barakos; Eleftheria Hatzimichael
Journal:  Diseases       Date:  2022-06-10

Review 6.  Bone Marrow Immunity and Myelodysplasia.

Authors:  Claude Lambert; Yuenv Wu; Carmen Aanei
Journal:  Front Oncol       Date:  2016-07-20       Impact factor: 6.244

Review 7.  Role of Distinct Natural Killer Cell Subsets in Anticancer Response.

Authors:  Helena Stabile; Cinzia Fionda; Angela Gismondi; Angela Santoni
Journal:  Front Immunol       Date:  2017-03-16       Impact factor: 7.561

Review 8.  STATs in NK-Cells: The Good, the Bad, and the Ugly.

Authors:  Dagmar Gotthardt; Veronika Sexl
Journal:  Front Immunol       Date:  2017-01-18       Impact factor: 7.561

9.  Imprint of 5-azacytidine on the natural killer cell repertoire during systemic treatment for high-risk myelodysplastic syndrome.

Authors:  Ebba Sohlberg; Aline Pfefferle; Sandra Andersson; Bettina C Baumann; Eva Hellström-Lindberg; Karl-Johan Malmberg
Journal:  Oncotarget       Date:  2015-10-27

10.  Abnormal populations and functions of natural killer cells in patients with myelodysplastic syndromes.

Authors:  Wei Zhang; Xinyan Xie; Huijing Mi; Jinwan Sun; Shaoxue Ding; Lijuan Li; Hui Liu; Huaquan Wang; Rong Fu; Zonghong Shao
Journal:  Oncol Lett       Date:  2018-02-15       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.